The complaint alleges that Embecta misled the market by issuing fiscal guidance for the second quarter and full-year 2026 without a reliable basis. According to the filing, company leadership was aware that specific market headwinds, particularly within the pen needle sector, threatened to undermine performance targets. These omissions reportedly resulted in material losses for shareholders once the actual market conditions were disclosed.

Schall, Brown & Schwartz LLP is currently organizing the class action and invites affected investors to discuss their legal standing. While participation does not require being named as lead plaintiff, those who suffered financial damages may contact partners Brian Schall or David Schwartz at the firm’s Los Angeles office. The class has not yet been certified, meaning investors who take no action remain absent class members without formal legal representation.